WNT5A and prostate carcinoma: WNT5A has been associated with increased resistance to chemotherapeutics in ovarian and breast cancer cells (Peng et al., 2011; Hung et al., 2014), and approaches of directly targeting WNT5A-mediated signaling for cancer therapy have been proposed for prostate cancer (Gao et al., 2022), small cell lung cancer (Kim et al., 2022) and melanoma (Jenei et al., 2009).